Sells VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, and develops genetic medicines for rare diseases affecting the skin, lungs and eyes.
10-K for FY2025, filed Feb 17, 2026We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and…View ↗
Our first commercial product, VYJUVEK®, is now approved in the United States, the European Union (“EU”), and Japan for the treatment of…View ↗
Our development pipeline includes multiple clinical stage product candidates for the treatment of rare and serious diseases, and we are…View ↗
VYJUVEK is a redosable, off-the-shelf gene therapy designed to deliver two copies of the COL7A1 gene when applied topically, directly onto…View ↗
Customers pay for VYJUVEK when it is delivered to them. The company sells it to specialty pharmacy providers, hospitals and specialty distributors.
10-K for FY2025, filed Feb 17, 2026
$389.1M
10-K for FY2025, filed Feb 17, 2026
$389.1M ↗
Specialty pharmacies, hospitals and specialty distributors buy VYJUVEK directly from the company; pharmacies prepare it for healthcare professionals, while hospitals and distributors supply hospital use.
10-K for FY2025, filed Feb 17, 2026The Company sells VYJUVEK to a limited number of specialty pharmacy (“SPs”) providers that mix the medication to be administered at a…View ↗
10-K for FY2025, filed Feb 17, 2026
Following FDA approval in May 2023, the Company began commercial marketing and sales of VYJUVEK and began recognizing revenue in the third…View ↗
Yes. It kept 53 cents of every revenue dollar as net income in FY2025 and turned 49 cents into free cash flow.
8-K, filed Jul 21, 2026
On July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in…View ↗
Competes with Abeona Therapeutics, Castle Creek Biosciences, BridgeBio Pharma, Chiesi Farmaceutici, RHEACELL, Vertex Pharmaceuticals, ReCode Therapeutics, Spirovant Sciences, 4D Molecular Therapeutics, CSL, Takeda Pharmaceutical, Grifols, Kamada, Sanofi, Peak Bio, Mereo BioPharma Group, Wave Life Sciences, Beam Therapeutics, Dompé farmaceutici, and Merck &
10-K for FY2025, filed Feb 17, 2026Corrective Approaches: We are aware of companies, Abeona Therapeutics Inc. and Castle Creek Biosciences, Inc., which are developing or have…View ↗
Loading...